June 01, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
In an early study, a tissue-engineered heart muscle product was linked to improvements in heart wall thickness, left ventricular ejection fraction and quality of life in patients with heart failure with reduced EF. Biologic ventricular assist tissue (Repairon) is “the first tissue-engineered heart muscle product in clinical trials” and the phase 1 to 2 BioVAT-HF study, published in
June 01, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Early report on modular BioVAT patches in advanced stage C or D disease

A stem cell-based heart patch improved pumping in a small trial for advanced heart failure. "Very good first step," researcher…

Thin sheets of engineered artificial tissue can be readily manufactured because they do not require a vasculature, perfusion of…

Treatments aim to bulk up failing hearts to restore their vigour – but can the field move on from past controversy?

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development…

Using patient-derived cardiac tissue and stem cell-based models, the team of translational researchers demonstrated that…

Gene therapies to fix failing hearts gain steam after years in the doldrums